ADVA
12.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it is playing a key role in a unique research initiative extending post-quantum security to VPN networks. Leveraging the ADVA FSP 150 with ConnectGuard™ Ethernet encryption, the Quantum-Secure VPN Modules and Operation Modes (QuaSiModO) project is testing new quantum-resistant algorithms in the packet domain. It will develop viable security solutions that can protect Layer 2 and 3 data against all forms of cyberattack, including those from quantum computers. By participating in the initiative, ADVA is extending its industry-leading work with quantum-safe cryptography in optical transport to higher network layers. Other QuaSiModO project partners are the Fraunhofer Institute of Applied and Integrated Security, the Ludwig Maximilian University of Munich and genua GmbH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005043/en/
“As part of the QuaSiModO project, we’re continuing to drive innovation in future-proof cryptography. This initiative extends comprehensive post-quantum security to VPNs and enables businesses and government institutions to protect their data from tomorrow’s attacks,” said Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Together with our partners, we’re ensuring that network security technology doesn’t fall behind in the computing power race. Our role in the project combines our experience with transport layer post-quantum security and our proven expertise when it comes to encrypting Carrier Ethernet connectivity. We’re helping to create a solution able to protect packet services today and ready to be upgraded later to comply with emerging specifications from standards bodies such as the USA’s National Institute of Standards and Technology.”
Quantum computers of sufficient size and reliability could arrive within the next 10 to 15 years. This may mean that today’s widely applied data protection technologies will no longer be sufficient. What’s more, sensitive and valuable information may be at risk right now from harvesting attacks, with attackers storing information today to decrypt it as soon as large quantum computers are available. Funded by the German Federal Ministry of Education and Research, the QuaSiModO project is researching, testing and helping to standardize quantum-resistant algorithms in VPN implementations. It aims to extend existing IPSec and MACsec communication protocols with quantum-resistant procedures and support the development of complete solutions. The initiative is utilizing ADVA FSP 150 edge devices with ConnectGuard™ Ethernet encryption technology based on an enhanced version of MACsec. The solution provides high throughput and low-latency performance as it encrypts across multiple domains and service provider networks.
“When quantum computers emerge, they’ll be able to quickly crack complex problems that would take today’s most powerful supercomputers many years to solve. That’s why enterprises, governments and communication service providers are looking to leverage security technology built on quantum-safe algorithms,” commented Alexander von Gernler, head of research, genua GmbH. “For a decade, we’ve been focused on the threat posed by large quantum computers, and much of our work in recent years has been about developing practical quantum-resistant signatures and key establishment protocols. Now, we’re leading the QuaSiModO consortium, working with ADVA and the other partners to bring post-quantum security to network Layers 2 and 3, and deliver the robust future-proof protection that classical encryption technologies simply can’t.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005043/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom